MALVERN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced updates to its Retina Scientific Advisory Board (SAB) and Executive Leadership Team to enhance external guidance from key opinion leaders and strengthen the Company’s internal expertise in critical functions and as it pursues its goal of three BLAs in the next three years. “As our novel modifier gene therapy programs ...

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Cadiz (CDZI) acquires and develops water-related land and agricultural assets. The Zacks Consensus Estimate for its current year earnings has been revised 40% downward over the last 60 days.ArriVent BioPharma, Inc. (AVBP) is a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The Zacks Cons ...

NCCN Clinical Practice Guidelines in Oncology for the Prevention and Treatment of Cancer-Related Infections now recommend monoclonal antibodies for pre-exposure prophylaxis against COVID-19 in appropriate cancer populationsReflects growing alignment among NCCN, IDSA, and CDC on the role of monoclonal antibodies in protecting immunocompromised individuals from COVID-19New data published online in JAMA Oncology from the National Cancer Institute COVID-19 in Cancer Patients Study showed COVID-19 had a signific ...

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced compelling immunologic findings from the treatment of a moderate Alzheimer's Disease (AD) patient with intranasal foralumab. Transcriptional analysis of white blood cells before and after foralumab th ...

CAMBRIDGE, Mass., July 21, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the first patient has been dosed in ALKAZAR, the company's global Phase 3 randomized, controlled trial evaluating neladalkib for TKI-naïve patients with advanced ALK-positive non-small cell lung cancer (NSCLC), versus ALECENSA® (alectinib), a front-line standard of care." ...

Group 1 - The China Securities 2000 Index (562660) has increased by 0.80%, with notable gains from stocks such as Guanlong Energy (+20.00%) and Deepwater Planning Institute (+20.00%) [1] - The China Securities 2000 ETF (562660) has risen by 1.31%, reaching a latest price of 1.47 yuan, with a trading volume of 518.24 million yuan and a turnover rate of 2.23% [1] - The latest scale of the China Securities 2000 ETF (562660) has reached 231 million yuan, marking a one-year high [1] Group 2 - The project "First Breakthrough of High-Temperature Gas-Cooled Reactor Main Equipment Forging" led by Shanghai Electric has successfully passed expert review, addressing high-performance requirements for main equipment forgings [2] - A series of policies aimed at expanding domestic demand and promoting consumption have been introduced, enhancing market vitality [2] - CITIC Securities suggests that the A-share market is transitioning to an incremental market, with a focus on sectors that can create consensus among investors post mid-year report season [2] Group 3 - The China Securities 2000 ETF closely tracks the China Securities 2000 Index, which selects 2000 small-cap stocks with high liquidity, presenting a complementary style to large and mid-cap indices [3] - The index emphasizes "specialized, refined, distinctive, and innovative" companies, with a high proportion of emerging industries such as machinery, electronics, and biomedicine, indicating significant growth potential [3] - The top ten constituent stocks account for less than 2% of the total weight, highlighting a notable risk diversification advantage [3]

长江商报消息 六年砥砺奋进，六年春华秋实。在中国资本市场改革发展史上，科创板的设立无疑具有 里程碑意义。作为注册制改革的"试验田"，科创板六年来始终坚守"硬科技"定位，以7.35万亿元总市 值、1.12万亿元融资规模的亮眼成绩，交出了一份服务科技创新的精彩答卷。 当前，科创板改革进入深化期。长江商报特推出"科创板六年"专题策划，期待这片创新沃土继续以制度 创新激发市场活力，以资本力量赋能科技创新。 ●长江商报记者 徐佳 2019年7月22日，科创板鸣锣开市，中国资本市场注册制改革的"试验田"应运而生。 六年来，科创板以"硬科技"为底色，通过制度创新重塑资本市场生态。不仅培育了一大批具有核心技术 的"硬科技"创新企业，更推动了全市场注册制改革的落地，成为中国经济转型升级的重要引擎。 2019年7月22日，随着首批25家公司挂牌上市交易，科创板正式开市，成为中国资本市场首个试点注册 制的板块。 六年以来，从最初的资本市场改革"试验田"到如今的"硬科技"主阵地，科创板实现了规模与质量的同步 跃升。 根据上交所数据，截至7月18日收盘，科创板共受理了969家企业的首发上市申请，其中589家公司已经 在科创板上市，总股 ...

NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action. Investors have until July 22, 2025, to ask the Court to be appointed to lea ...

NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Investors have until August 25, 2025, to as ...

Core Viewpoint - Viking Therapeutics has experienced significant stock volatility, with shares down nearly 60% since October of last year and 68% from early 2024 highs, despite a promising drug pipeline [1][2][3] Company Overview - Viking Therapeutics is a pre-revenue biopharma company with a market cap of $3.5 billion, focusing on developing treatments for rare metabolic and endocrine disorders [3][4] - The company is currently testing four different drugs across five clinical trials, with its lead candidate VK2735, an injectable anti-obesity drug, in phase 3 testing [4][5] Market Dynamics - The stock's volatility is attributed to market reactions to the drug's development progress, with investors often overreacting to news, leading to sharp price fluctuations [7][8] - Historical patterns in biopharma stocks suggest that significant price drops can precede a recovery, especially when the underlying drug shows potential [2][14] Competitive Landscape - Viking's VK2735 competes with established obesity drugs from Novo Nordisk and Eli Lilly, but there is potential for market share due to consumer willingness to try alternatives [15][16] - The global weight-loss drug market is projected to grow from $15 billion to $150 billion by 2035, indicating substantial growth opportunities for Viking Therapeutics [16] Future Outlook - The stock is expected to rally within a two-year timeframe as meaningful updates on VK2735's phase 3 testing are anticipated [17] - Concerns regarding the cost of manufacturing VK2735 in both injectable and oral forms may be overstated, given the projected demand in the market [18]